Glukagonlignende peptid 1-receptoragonisten semaglutid

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

Glukagonlignende peptid 1-receptoragonisten semaglutid. / Boje, Amalie Dyhrberg; Juhl, Christian Rimer; Torekov, Signe Sørensen; Madsbad, Sten.

In: Ugeskrift for Laeger, Vol. 181, V03190155, 2019.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Boje, AD, Juhl, CR, Torekov, SS & Madsbad, S 2019, 'Glukagonlignende peptid 1-receptoragonisten semaglutid', Ugeskrift for Laeger, vol. 181, V03190155. <https://ugeskriftet.dk/videnskab/glukagonlignende-peptid-1-receptoragonisten-semaglutid>

APA

Boje, A. D., Juhl, C. R., Torekov, S. S., & Madsbad, S. (2019). Glukagonlignende peptid 1-receptoragonisten semaglutid. Ugeskrift for Laeger, 181, [V03190155]. https://ugeskriftet.dk/videnskab/glukagonlignende-peptid-1-receptoragonisten-semaglutid

Vancouver

Boje AD, Juhl CR, Torekov SS, Madsbad S. Glukagonlignende peptid 1-receptoragonisten semaglutid. Ugeskrift for Laeger. 2019;181. V03190155.

Author

Boje, Amalie Dyhrberg ; Juhl, Christian Rimer ; Torekov, Signe Sørensen ; Madsbad, Sten. / Glukagonlignende peptid 1-receptoragonisten semaglutid. In: Ugeskrift for Laeger. 2019 ; Vol. 181.

Bibtex

@article{6d9ebaace7b1423598a8a8a53b5a50e4,
title = "Glukagonlignende peptid 1-receptoragonisten semaglutid",
abstract = "Semaglutide is a glucagon-like peptide-1 receptor-agonist (GLP-1 RA), which is injected subcutaneously once a week for treatment of Type 2 diabetes. In this review, the present results of semaglutide treatment are presented. Semaglutide has been evaluated in more than 8,000 patients across the spectrum of Type 2 diabetes. Trials with semaglutide have demonstrated superiority with sustained improved glycaemic control and weight loss compared to oral antidiabetic agents, other GLP-1 RAs and basalinsulin. In addition, semaglutide significantly decreased the occurrence of cardiovascular events compared with standard pharmacological diabetic treatment combined with placebo.",
keywords = "Blood Glucose, Diabetes Mellitus, Type 2/drug therapy, Glucagon-Like Peptide-1 Receptor, Glucagon-Like Peptides/therapeutic use, Humans, Hypoglycemic Agents/therapeutic use",
author = "Boje, {Amalie Dyhrberg} and Juhl, {Christian Rimer} and Torekov, {Signe S{\o}rensen} and Sten Madsbad",
year = "2019",
language = "Dansk",
volume = "181",
journal = "Ugeskrift for Laeger",
issn = "0041-5782",
publisher = "Almindelige Danske Laegeforening",

}

RIS

TY - JOUR

T1 - Glukagonlignende peptid 1-receptoragonisten semaglutid

AU - Boje, Amalie Dyhrberg

AU - Juhl, Christian Rimer

AU - Torekov, Signe Sørensen

AU - Madsbad, Sten

PY - 2019

Y1 - 2019

N2 - Semaglutide is a glucagon-like peptide-1 receptor-agonist (GLP-1 RA), which is injected subcutaneously once a week for treatment of Type 2 diabetes. In this review, the present results of semaglutide treatment are presented. Semaglutide has been evaluated in more than 8,000 patients across the spectrum of Type 2 diabetes. Trials with semaglutide have demonstrated superiority with sustained improved glycaemic control and weight loss compared to oral antidiabetic agents, other GLP-1 RAs and basalinsulin. In addition, semaglutide significantly decreased the occurrence of cardiovascular events compared with standard pharmacological diabetic treatment combined with placebo.

AB - Semaglutide is a glucagon-like peptide-1 receptor-agonist (GLP-1 RA), which is injected subcutaneously once a week for treatment of Type 2 diabetes. In this review, the present results of semaglutide treatment are presented. Semaglutide has been evaluated in more than 8,000 patients across the spectrum of Type 2 diabetes. Trials with semaglutide have demonstrated superiority with sustained improved glycaemic control and weight loss compared to oral antidiabetic agents, other GLP-1 RAs and basalinsulin. In addition, semaglutide significantly decreased the occurrence of cardiovascular events compared with standard pharmacological diabetic treatment combined with placebo.

KW - Blood Glucose

KW - Diabetes Mellitus, Type 2/drug therapy

KW - Glucagon-Like Peptide-1 Receptor

KW - Glucagon-Like Peptides/therapeutic use

KW - Humans

KW - Hypoglycemic Agents/therapeutic use

M3 - Tidsskriftartikel

C2 - 31610830

VL - 181

JO - Ugeskrift for Laeger

JF - Ugeskrift for Laeger

SN - 0041-5782

M1 - V03190155

ER -

ID: 241276061